RhumbLine Advisers
VTGN icon

RhumbLine Advisers’s VistaGen Therapeutics VTGN Stock Holding History

RhumbLine Advisers’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,225
Closed -$56.5K – 4361
2023
Q2 		$56.5K Buy
30,225
+21,600
+250% +$75.7K ﹤0.01% 3655
2023
Q1 		$32K Buy
8,625
+535
+7% +$2.81K ﹤0.01% 2923
2022
Q4 		$25K Buy
8,090
+139
+2% +$523 ﹤0.01% 2977
2022
Q3 		$36K Buy
7,951
+558
+8% +$5.53K ﹤0.01% 3054
2022
Q2 		$195K Buy
7,393
+964
+15% +$34K ﹤0.01% 2933
2022
Q1 		$239K Buy
6,429
+1,195
+23% +$52.1K ﹤0.01% 2712
2021
Q4 		$306K Sell
5,234
-108
-2% -$7.03K ﹤0.01% 2696
2021
Q3 		$439K Buy
5,342
+587
+12% +$51K ﹤0.01% 2607
2021
Q2 		$449K Buy
+4,755
New +$352K ﹤0.01% 2608

Other funds holding VTGN

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's VTGN Position: Q3 2023 in Review

RhumbLine Advisers sold out of VistaGen Therapeutics (VTGN) in Q3 2023, closing a stake of 30,225 shares — an estimated $56.5K sold.

RhumbLine Advisers first reported a position in VTGN in Q2 2021 and held it in 9 quarters. The position peaked at $449K in Q2 2021. 34 funds tracked by Wall St. Rank hold VTGN as of Q3 2023.

  • RhumbLine Advisers reported no remaining VistaGen Therapeutics position as of Q3 2023 after selling out during the quarter.
  • RhumbLine Advisers sold 30,225 VistaGen Therapeutics shares in Q3 2023, an estimated $56.5K.
  • RhumbLine Advisers first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 9 quarters.
  • RhumbLine Advisers's VistaGen Therapeutics position peaked at $449K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2023.

Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.